Heart Care

Developing technology that continually improves
the diagnostic & treatment of cardiac diseases

Simple tools with augmented image guidance to help your daily practice. These tools may improve
diagnosis accuracy, simplify navigation in complex anatomies, and increase precision of device
positioning which could lead to improved outcomes for all of your cardiac interventions.

CVD is the most common cause of death worldwide(1)

  • 50% of untreated patients with onset symptoms of Aortic Stenosis die within 2 years2
  • 5 Million Americans are diagnosed with aortic valve stenosis each year2

Minimally invasive therapies for CVD are increasing

Portfolio of Solutions
dedicated to Interventional Cardiology

Find the right IGS series for your cardiac interventions

Optima™ 3 IGS Series*

EXPLORE

Versatility within your reach
Optima™ IGS 320
Optima™ IGS 330

Innova™ IGS 5

EXPLORE

As flexible as it is powerful
IGS 520
IGS 530
IGS 540

Innova™ IGS 6

EXPLORE

Biplane image-guided system
IGS 620
IGS 630

Discovery IGS™ 7

EXPLORE

Free yourself from the rails
IGS 730
IGS 740

Discovery IGS™ 7 OR

EXPLORE

Rediscover space and movement
IGS 730 OR
IGS 740 OR

Diagnostics & PCI

Main challenges in Coronary Angiography

Structural Heart

Main challenges in Structural Heart
  1. Most common cause of death worldwide. http://www.who.int/cardiovascular_diseases/en/
  2. According to the American Heart Association (AHA), more than 5 million Americans are diagnosed with aortic valve stenosis each year. An estimated 1.5 million people suffer from aortic stenosis in the United States with prevalence of 5% over 75 years of age. Patients with aortic stenosis have congested blood flow across the aortic
    valve in the heart and are at high surgical risk. Over 10 to 20 years, these patients experience noticeable symptoms, such as chest pain and heart failure, with mortality
    rates at 1 year and 2 years at approximately 25% and 50%, respectively. The Global Emerging Interventional Cardiac Devices Market Increasing Adoption of New
    Technologies in Emerging Markets Provides Impetus to Growth - Frost & Sullivan - ND01-54 - February 2014

* IGS 3 series refer to Optima IGS 320 or Optima IGS 330